
Sprint Bioscience (Q3 review) - Gilead deal a strong confirmation

Redeye returns with an update on Sprint Bioscience following recent events and the Q3 report. We are impressed the recent progress that includes selling the TREX1 program to Gilead Sciences. With a robust cash position, the company should have more breathing room to continue with its internal programs and business development. We raise our base case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Sprint Bioscience (Q3 review) - Gilead deal a strong confirmation